Hence, unlike CD33 and CD123 showing broader expression outside the hematopoietic system,54 CD37 distribution seems to be restricted to terminally differentiated blood cells,21,22 making CD37 an attractive target for cell therapy in AML. This evidence concerns the gene CD37 and acute myeloid leukemia.